46 results on '"Mulder, Maxim J. H. L."'
Search Results
2. Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack.
- Author
-
Mulder, Maxim J. H. L., Cras, Tim Y., Shay, James, Dippel, Diederik W. J., and Burke, James F.
- Subjects
- *
TRANSIENT ischemic attack , *ISCHEMIC stroke , *SECONDARY prevention , *MYOCARDIAL infarction , *MEDICAL research - Abstract
Guidelines help to facilitate treatment decisions based on available evidence, and also to provide recommendations in areas of uncertainty. In this paper, we compare the recommendations for stroke workup and secondary prevention of ischemic stroke and transient ischemic attack of the American Heart Association (AHA)/American Stroke Association (ASA) with the European Stroke Organization (ESO) guidelines. The primary aim of this paper is to offer clinicians guidance by identifying areas where there is consensus and where consensus is lacking, in the absence or presence of high-level evidence. We compared AHA/ASA with the ESO guideline recommendations for 7 different topics related to diagnostic stroke workup and secondary prevention. We categorized the recommendations based on class and level of evidence to determine whether there were relevant differences in the ratings of evidence that the guidelines used for its recommendations. Finally, we summarized major topics of agreement and disagreement, while also prominent knowledge gaps were identified. In total, we found 63 ESO and 82 AHA/ASA recommendations, of which 38 were on the same subject. Most recommendations are largely similar, but not all are based on high-level evidence. For many recommendations, AHA/ASA and ESO assigned different levels of evidence. For the 10 recommendations with Level A evidence (high quality) in AHA/ASA, ESO only labeled 4 of these as high quality. There are many remaining issues with either no or insufficient evidence, and some topics that are not covered by both guidelines. Most ESO and AHA/ASA Guideline recommendations for stroke workup and secondary prevention were similar. However not all were based on high-level evidence and the appointed level of evidence often differed. Clinicians should not blindly follow all guideline recommendations; the accompanying level of evidence informs which recommendations are based on robust evidence. Topics with lower levels of evidence, or those with recommendations that disagree or are missing, may be an incentive for further clinical research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Association between thrombus composition and stroke etiology in the MR CLEAN Registry biobank
- Author
-
Hund, Hajo M., Boodt, Nikki, Hansen, Daniel, Haffmans, Willem A., Lycklama à Nijeholt, Geert J., Hofmeijer, Jeannette, Dippel, Diederik W. J., van der Lugt, Aad, van Es, Adriaan C. G. M., van Beusekom, Heleen M. M., Majoie, Charles B. L. M., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Boiten, Jelis, Vos, Jan Albert, Jansen, Ivo G. H., Mulder, Maxim J. H. L., Goldhoorn, Robert- Jan B., Compagne, Kars C. J., Kappelhof, Manon, Brouwer, Josje, den Hartog, Sanne J., Hinsenveld, Wouter H., Roozenbeek, Bob, Emmer, Bart J., Coutinho, Jonathan M., Schonewille, Wouter J., Wermer, Marieke J. H., van Walderveen, Marianne A. A., Staals, Julie, Martens, Jasper M., de Bruijn, Sebastiaan F., van Dijk, Lukas C., van der Worp, H. Bart, Lo, Rob H., van Dijk, Ewoud J., Boogaarts, Hieronymus D., de Vries, J., de Kort, Paul L. M., van Tuijl, Julia, Peluso, Jo P., Fransen, Puck, van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, René J., Uyttenboogaart, Maarten, Eschgi, Omid, Bokkers, Reinoud P. H., Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Keizer, Koos, Yo, Lonneke S. F., den Hertog, Heleen M., Bulut, Tomas, Brouwers, Paul J. A. M., Sprengers, Marieke E. S., Jenniskens, Sjoerd F. M., van den Berg, René, Yoo, Albert J., Beenen, Ludo F. M., Postma, Alida A., Roosendaal, Stefan D., van der Kallen, Bas F. W., van den Wijngaard, Ido R., Bot, Joost, van Doormaal, Pieter-Jan, Meijer, Anton, Ghariq, Elyas, van Proosdij, Marc P., Krietemeijer, G. Menno, Dinkelaar, Wouter, Appelman, Auke P. A., Hammer, Bas, Pegge, Sjoert, van der Hoorn, Anouk, Vinke, Saman, Flach, H. Zwenneke, Lingsma, Hester F., el Ghannouti, Naziha, Sterrenberg, Martin, Pellikaan, Wilma, Sprengers, Rita, Elfrink, Marjan, Simons, Michelle, Vossers, Marjolein, de Meris, Joke, Vermeulen, Tamara, Geerlings, Annet, van Vemde, Gina, Simons, Tiny, Messchendorp, Gert, Nicolaij, Nynke, Bongenaar, Hester, Bodde, Karin, Kleijn, Sandra, Lodico, Jasmijn, Droste, Hanneke, Wollaert, Maureen, Verheesen, Sabrina, Jeurrissen, D., Bos, Erna, Drabbe, Yvonne, Sandiman, Michelle, Aaldering, Nicoline, Zweedijk, Berber, Vervoort, Jocova, Ponjee, Eva, Romviel, Sharon, Kanselaar, Karin, Barning, Denn, Venema, Esmee, Chalos, Vicky, Geuskens, Ralph R., van Straaten, Tim, Ergezen, Saliha, Harmsma, Roger R. M., Muijres, Daan, de Jong, Anouk, Berkhemer, Olvert A., Boers, Anna M. M., Huguet, J., Groot, P. F. C., Mens, Marieke A., van Kranendonk, Katinka R., Treurniet, Kilian M., Tolhuisen, Manon L., Alves, Heitor, Weterings, Annick J., Kirkels, Eleonora L.F., Voogd, Eva J. H. F., Schupp, Lieve M., Collette, Sabine L., Groot, Adrien E. D., LeCouffe, Natalie E., Konduri, Praneeta R., Prasetya, Haryadi, Arrarte-Terreros, Nerea, Ramos, Lucas A., Radiology and Nuclear Medicine, ACS - Microcirculation, ANS - Neurovascular Disorders, Neurology, ACS - Atherosclerosis & ischemic syndromes, ANS - Cellular & Molecular Mechanisms, ANS - Compulsivity, Impulsivity & Attention, Graduate School, Biomedical Engineering and Physics, AMS - Amsterdam Movement Sciences, ANS - Brain Imaging, Adult Psychiatry, APH - Methodology, Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Cardiology, Radiology & Nuclear Medicine, Radiology and nuclear medicine, Internal medicine, Pediatrics, Amsterdam Neuroscience - Neurovascular Disorders, and CCA - Imaging and biomarkers
- Subjects
Microscopy ,Ischemic stroke ,Radiology, Nuclear Medicine and imaging ,Endovascular treatment ,Neurology (clinical) ,Cardiology and Cardiovascular Medicine ,Mechanical thrombectomy ,Stent-retriever ,Thrombus - Abstract
Purpose The composition of thrombi retrieved during endovascular thrombectomy (EVT) in acute ischemic stroke (AIS) due to large vessel occlusion (LVO) may differ depending on their origin. In this study, we investigated the association between thrombus composition and stroke etiology in a large population of patients from the Dutch MR CLEAN Registry treated with EVT in daily clinical practice. Methods The thrombi of 332 patients with AIS were histologically analyzed for red blood cells (RBC), fibrin/platelets (F/P), and white blood cells (leukocytes) using a machine learning algorithm. Stroke etiology was assessed using the Trial of Org 10,172 in acute stroke treatment (TOAST) classification. Results The thrombi of cardioembolic origin contained less RBC and more F/P than those of non-cardioembolic origin (25.8% vs 41.2% RBC [p = 0.003] and 67.1% vs 54.5% F/P [p = 0.004]). The likelihood of a non-cardioembolic source of stroke increased with increasing thrombus RBC content (OR 1.02; [95% CI 1.00–1.06] for each percent increase) and decreased with a higher F/P content (OR 1.02; [95% CI 1.00–1.06]). Thrombus composition in patients with a cardioembolic origin and undetermined origin was similar. Conclusion Thrombus composition is significantly associated with stroke etiology, with an increase in RBC and a decrease in F/P raising the odds for a non-cardioembolic cause. No difference between composition of cardioembolic thrombi and of undetermined origin was seen. This emphasizes the need for more extensive monitoring for arrhythmias and/or extended cardiac analysis in case of an undetermined origin.
- Published
- 2023
- Full Text
- View/download PDF
4. Clinical consequence of vessel perforations during endovascular treatment of acute ischemic stroke.
- Author
-
van der Sluijs, P. Matthijs, Su, R., Cornelissen, S. A. P., van Es, A. C. G. M., Lycklama a Nijeholt, G., Roozenbeek, B., van Doormaal, P. J., Hofmeijer, J., van der Lugt, A., van Walsum, T., On Behalf Of the MR CLEAN Registry investigators, Dippel, Diederik W. J., Majoie, Charles B. L. M., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Boiten, Jelis, Vos, Jan Albert, Jansen, Ivo G. H., and Mulder, Maxim J. H. L.
- Subjects
REPORTING of diseases ,CEREBRAL angiography ,ISCHEMIC stroke ,SURGICAL complications ,TREATMENT effectiveness ,RISK assessment ,THROMBECTOMY ,CATHETERIZATION complications ,RESEARCH funding ,ENDOVASCULAR surgery ,LOGISTIC regression analysis ,ODDS ratio ,CEREBRAL ischemia ,DISEASE risk factors - Abstract
Purpose: Endovascular treatment (EVT) of acute ischemic stroke can be complicated by vessel perforation. We studied the incidence and determinants of vessel perforations. In addition, we studied the association of vessel perforations with functional outcome, and the association between location of perforation on digital subtraction angiography (DSA) and functional outcome, using a large EVT registry. Methods: We included all patients in the MR CLEAN Registry who underwent EVT. We used DSA to determine whether EVT was complicated by a vessel perforation. We analyzed the association with baseline clinical and interventional parameters using logistic regression models. Functional outcome was measured using the modified Rankin Scale at 90 days. The association between vessel perforation and angiographic imaging features and functional outcome was studied using ordinal logistic regression models adjusted for prognostic parameters. These associations were expressed as adjusted common odds ratios (acOR). Results: Vessel perforation occurred in 74 (2.6%) of 2794 patients who underwent EVT. Female sex (aOR 2.0 (95% CI 1.2–3.2)) and distal occlusion locations (aOR 2.2 (95% CI 1.3–3.5)) were associated with increased risk of vessel perforation. Functional outcome was worse in patients with vessel perforation (acOR 0.38 (95% CI 0.23–0.63)) compared to patients without a vessel perforation. No significant association was found between location of perforation and functional outcome. Conclusion: The incidence of vessel perforation during EVT in this cohort was low, but has severe clinical consequences. Female patients and patients treated at distal occlusion locations are at higher risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Validity of Early Outcomes as Indicators for Comparing Hospitals on Quality of Stroke Care
- Author
-
Amini, Marzyeh, primary, Eijkenaar, Frank, additional, Lingsma, Hester F., additional, den Hartog, Sanne J., additional, Olthuis, Susanne G. H., additional, Martens, Jasper, additional, van der Worp, Bart, additional, van Zwam, Wim, additional, van der Hoorn, Anouk, additional, Roosendaal, Stefan D., additional, Roozenbeek, Bob, additional, Dippel, Diederik, additional, van Leeuwen, Nikki, additional, Dippel, Diederik W. J., additional, van der Lugt, Aad, additional, Majoie, Charles B. L. M., additional, Roos, Yvo B. W. E. M., additional, van Oostenbrugge, Robert J., additional, van Zwam, Wim H., additional, Boiten, Jelis, additional, Vos, Jan Albert, additional, Brouwer, Josje, additional, Hinsenveld, Wouter H., additional, Kappelhof, Manon, additional, Compagne, Kars C. J., additional, Goldhoorn, Robert‐Jan B., additional, Mulder, Maxim J. H. L., additional, Jansen, Ivo G. H., additional, van Es, Adriaan C. G. M., additional, Emmer, Bart J., additional, Coutinho, Jonathan M., additional, Schonewille, Wouter J., additional, Wermer, Marieke J. H., additional, van Walderveen, Marianne A. A., additional, Staals, Julie, additional, Hofmeijer, Jeannette, additional, Martens, Jasper M., additional, Lycklama à Nijeholt, Geert J., additional, de Bruijn, Sebastiaan F., additional, van Dijk, Lukas C., additional, van der Worp, H. Bart, additional, Lo, Rob H., additional, van Dijk, Ewoud J., additional, Boogaarts, Hieronymus D., additional, de Vries, J., additional, de Kort, Paul L. M., additional, van Tuijl, Julia, additional, Peluso, Jo Jo P., additional, Fransen, Puck, additional, van den Berg, Jan S. P., additional, van Hasselt, Boudewijn A. A. M., additional, Aerden, Leo A. M., additional, Dallinga, René J., additional, Uyttenboogaart, Maarten, additional, Eschgi, Omid, additional, Bokkers, Reinoud P. H., additional, Schreuder, Tobien H. C. M. L., additional, Heijboer, Roel J. J., additional, Keizer, Koos, additional, Yo, Lonneke S. F., additional, den Hertog, Heleen M., additional, Sturm, Emiel J. C., additional, Brouwers, Paul, additional, Sprengers, Marieke E. S., additional, Jenniskens, Sjoerd F. M., additional, van den Berg, René, additional, Yoo, Albert J., additional, Beenen, Ludo F. M., additional, Postma, Alida A., additional, van der Kallen, Bas F. W., additional, van den Wijngaard, Ido R., additional, Bot, Joost, additional, van Doormaal, Pieter‐Jan, additional, Meijer, Anton, additional, Ghariq, Elyas, additional, van Proosdij, Marc P., additional, Krietemeijer, G. Menno, additional, Peluso, Jo P., additional, Lo, Rob, additional, Dinkelaar, Wouter, additional, Appelman, Auke P. A., additional, Hammer, Bas, additional, Pegge, Sjoert, additional, Vinke, Saman, additional, Flach, H. Zwenneke, additional, el Ghannouti, Naziha, additional, Sterrenberg, Martin, additional, Puppels, Corina, additional, Pellikaan, Wilma, additional, Sprengers, Rita, additional, Elfrink, Marjan, additional, Simons, Michelle, additional, Vossers, Marjolein, additional, de Meris, Joke, additional, Vermeulen, Tamara, additional, Geerlings, Annet, additional, van Vemde, Gina, additional, Simons, Tiny, additional, van Rijswijk, Cathelijn, additional, Messchendorp, Gert, additional, Nicolaij, Nynke, additional, Bongenaar, Hester, additional, Bodde, Karin, additional, Kleijn, Sandra, additional, Lodico, Jasmijn, additional, Droste, Hanneke, additional, Wollaert, Maureen, additional, Verheesen, Sabrina, additional, Jeurrissen, D., additional, Bos, Erna, additional, Drabbe, Yvonne, additional, Sandiman, Michelle, additional, Aaldering, Nicoline, additional, Zweedijk, Berber, additional, Khalilzada, Mostafa, additional, Vervoort, Jocova, additional, Ponjee, Eva, additional, Romviel, Sharon, additional, Kanselaar, Karin, additional, Barning, Denn, additional, Venema, Esmee, additional, Chalos, Vicky, additional, Geuskens, Ralph R., additional, van Straaten, Tim, additional, Ergezen, Saliha, additional, Harmsma, Roger R. M., additional, Muijres, Daan, additional, de Jong, Anouk, additional, Berkhemer, Olvert A., additional, Boers, Anna M. M., additional, Huguet, J., additional, Groot, P. F. C., additional, Mens, Marieke A., additional, van Kranendonk, Katinka R., additional, Treurniet, Kilian M., additional, Tolhuisen, Manon L., additional, Alves, Heitor, additional, Weterings, Annick J., additional, Kirkels, Eleonora L. F., additional, Voogd, Eva J. H. F., additional, Schupp, Lieve M., additional, Collette, Sabine, additional, Groot, Adrien E. D., additional, LeCouffe, Natalie E., additional, Konduri, Praneeta R., additional, Prasetya, Haryadi, additional, Arrarte‐Terreros, Nerea, additional, and Ramos, Lucas A., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic Stroke.
- Author
-
Chalos, Vicky, Venema, Esmee, Mulder, Maxim J. H. L., Roozenbeek, Bob, Steyerberg, Ewout W., Wermer, Marieke J. H., Lycklama à Nijeholt, Geert J., van der Worp, H. Bart, Goyal, Mayank, Campbell, Bruce C. V., Muir, Keith W., Guillemin, Francis, Bracard, Serge, White, Philip, Dávalos, Antoni, Jovin, Tudor G., Hill, Michael D., Mitchell, Peter J., Demchuk, Andrew M., and Saver, Jeffrey L.
- Published
- 2023
- Full Text
- View/download PDF
7. Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry)
- Author
-
Jansen, Ivo G H, Mulder, Maxim J H L, and Goldhoorn, Robert-Jan B
- Published
- 2018
- Full Text
- View/download PDF
8. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy
- Author
-
Bastiaansen, Anna E M, de Bruijn, Marienke A A M, Schuller, Sabine L, Martinez-Hernandez, Eugenia, Brenner, Juliëtte, Paunovic, Manuela, Crijnen, Yvette S, Mulder, Maxim J H L, Schreurs, Marco W J, de Graaff, Esther, Smitt, Peter A E, Neuteboom, Rinze F, de Vries, Juna M, Titulaer, Maarten J, Sub Cell Biology, Celbiologie, Neurology, Immunology, Sub Cell Biology, and Celbiologie
- Subjects
Adult ,Male ,Adolescent ,Clinical Neurology ,Anti-N-Methyl-D-Aspartate Receptor Encephalitis/blood ,Netherlands/epidemiology ,Article ,Cohort Studies ,Young Adult ,Neoplasms ,Diagnosis ,80 and over ,Humans ,Age of Onset ,Preschool ,Child ,Netherlands ,Aged ,Autoantibodies ,Anti-N-Methyl-D-Aspartate Receptor Encephalitis ,Aged, 80 and over ,Infant ,Frequency ,Middle Aged ,Neurology ,Child, Preschool ,Aspartate receptor encephalitis ,Female ,Neurology (clinical) ,Autoantibodies/blood ,Neoplasms/epidemiology - Abstract
Background and ObjectivesTo describe the clinical features of anti-NMDAR encephalitis, emphasizing on late-onset patients and antibody test characteristics in serum and CSF.MethodsNationwide observational Dutch cohort study, in patients diagnosed with anti-NMDAR encephalitis between 2007 and 2019.ResultsOne hundred twenty-six patients with anti-NMDAR encephalitis were included with a median age of 24 years (range 1–86 years). The mean annual incidence was 1.00/million (95% CI 0.62–1.59). Patients ≥45 years of age at onset (19%) had fewer seizures (46% vs 71%, p = 0.021), fewer symptoms during disease course (3 vs 6 symptoms, p = 0.020), and more often undetectable serum antibodies compared with younger patients (p = 0.031). In the late-onset group, outcome was worse, and all tumors were carcinomas (both p < 0.0001). CSF was more accurate than serum to detect anti-NMDAR encephalitis (sensitivity 99% vs 68%, p < 0.0001). Using cell-based assay (CBA), CSF provided an unconfirmed positive test result in 11/2,600 patients (0.4%); 6/11 had a neuroinflammatory disease (other than anti-NMDAR encephalitis). Patients with anti-NMDAR encephalitis, who tested positive in CSF only, had lower CSF antibody titers (p = 0.003), but appeared to have an equally severe disease course.DiscussionAnti-NMDAR encephalitis occurs at all ages and is less rare in the elderly patients than initially anticipated. In older patients, the clinical phenotype is less outspoken, has different tumor association, and a less favorable recovery. Detection of antibodies in CSF is the gold standard, and although the CBA has very good validity, it is not perfect. The clinical phenotype should be leading, and confirmation in a research laboratory is recommended, when in doubt.
- Published
- 2022
9. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy
- Author
-
Sub Cell Biology, Celbiologie, Bastiaansen, Anna E M, de Bruijn, Marienke A A M, Schuller, Sabine L, Martinez-Hernandez, Eugenia, Brenner, Juliëtte, Paunovic, Manuela, Crijnen, Yvette S, Mulder, Maxim J H L, Schreurs, Marco W J, de Graaff, Esther, Smitt, Peter A E, Neuteboom, Rinze F, de Vries, Juna M, Titulaer, Maarten J, Sub Cell Biology, Celbiologie, Bastiaansen, Anna E M, de Bruijn, Marienke A A M, Schuller, Sabine L, Martinez-Hernandez, Eugenia, Brenner, Juliëtte, Paunovic, Manuela, Crijnen, Yvette S, Mulder, Maxim J H L, Schreurs, Marco W J, de Graaff, Esther, Smitt, Peter A E, Neuteboom, Rinze F, de Vries, Juna M, and Titulaer, Maarten J
- Published
- 2022
10. Hospital Variation in Time to Endovascular Treatment for Ischemic Stroke: What Is the Optimal Target for Improvement?
- Author
-
den Hartog, Sanne J., primary, Lingsma, Hester F., additional, van Doormaal, Pieter‐Jan, additional, Hofmeijer, Jeannette, additional, Yo, Lonneke S. F., additional, Majoie, Charles B. L. M., additional, Dippel, Diederik W. J., additional, van der Lugt, Aad, additional, Roozenbeek, Bob, additional, Roos, Yvo B. W. E. M., additional, van Oostenbrugge, Robert J., additional, van Zwam, Wim H., additional, Boiten, Jelis, additional, Vos, Jan Albert, additional, Jansen, Ivo G. H., additional, Mulder, Maxim J. H. L., additional, Goldhoorn, Robert‐ Jan B., additional, Compagne, Kars C. J., additional, Kappelhof, Manon, additional, Brouwer, Josje, additional, den Hartog, Sanne J., additional, Hinsenveld, Wouter H., additional, van Es, Adriaan C. G. M., additional, Emmer, Bart J., additional, Coutinho, Jonathan M., additional, Schonewille, Wouter J., additional, Wermer, Marieke J. H., additional, van Walderveen, Marianne A. A., additional, Staals, Julie, additional, Martens, Jasper M., additional, Lycklama à Nijeholt, Geert J., additional, de Bruijn, Sebastiaan F., additional, van Dijk, Lukas C., additional, van der Worp, H. Bart, additional, Lo, Rob H., additional, van Dijk, Ewoud J., additional, Boogaarts, Hieronymus D., additional, de Vries, J., additional, de Kort, Paul L. M., additional, van Tuijl, Julia, additional, Peluso, Jo P., additional, Fransen, Puck, additional, van den Berg, Jan S. P., additional, van Hasselt, Boudewijn A. A. M., additional, Aerden, Leo A. M., additional, Dallinga, René J., additional, Uyttenboogaart, Maarten, additional, Eschgi, Omid, additional, Bokkers, Reinoud P. H., additional, Schreuder, Tobien H. C. M. L., additional, Heijboer, Roel J. J., additional, Keizer, Koos, additional, den Hertog, Heleen M., additional, Sturm, Emiel J. C., additional, Brouwers, Paul J. A. M., additional, Sprengers, Marieke E. S., additional, Jenniskens, Sjoerd F. M., additional, van den Berg, René, additional, Yoo, Albert J., additional, Beenen, Ludo F. M., additional, Postma, Alida A., additional, Roosendaal, Stefan D., additional, van der Kallen, Bas F. W., additional, van den Wijngaard, Ido R., additional, Bot, Joost, additional, Meijer, Anton, additional, Ghariq, Elyas, additional, van Proosdij, Marc P., additional, Menno Krietemeijer, G., additional, Gerrits, Dick, additional, Dinkelaar, Wouter, additional, Appelman, Auke P. A., additional, Hammer, Bas, additional, Pegge, Sjoert, additional, van der Hoorn, Anouk, additional, Vinke, Saman, additional, Zwenneke Flach, H, additional, Ghannouti, Naziha el, additional, Sterrenberg, Martin, additional, Pellikaan, Wilma, additional, Sprengers, Rita, additional, Elfrink, Marjan, additional, Simons, Michelle, additional, Vossers, Marjolein, additional, de Meris, Joke, additional, Vermeulen, Tamara, additional, Geerlings, Annet, additional, van Vemde, Gina, additional, Simons, Tiny, additional, Messchendorp, Gert, additional, Nicolaij, Nynke, additional, Bongenaar, Hester, additional, Bodde, Karin, additional, Kleijn, Sandra, additional, Lodico, Jasmijn, additional, Droste, Hanneke, additional, Wollaert, Maureen, additional, Verheesen, Sabrina, additional, Jeurrissen, D., additional, Bos, Erna, additional, Drabbe, Yvonne, additional, Sandiman, Michelle, additional, Aaldering, Nicoline, additional, Zweedijk, Berber, additional, Vervoort, Jocova, additional, Ponjee, Eva, additional, Romviel, Sharon, additional, Kanselaar, Karin, additional, Barning, Denn, additional, Venema, Esmee, additional, Chalos, Vicky, additional, Geuskens, Ralph R., additional, van Straaten, Tim, additional, Ergezen, Saliha, additional, Harmsma, Roger R. M., additional, Muijres, Daan, additional, de Jong, Anouk, additional, Berkhemer, Olvert A., additional, Boers, Anna M. M., additional, Huguet, J., additional, Groot, P. F. C., additional, Mens, Marieke A., additional, van Kranendonk, Katinka R., additional, Treurniet, Kilian M., additional, Tolhuisen, Manon L., additional, Alves, Heitor, additional, Weterings, Annick J., additional, Kirkels, Eleonora L. F., additional, Voogd, Eva J. H. F., additional, Schupp, Lieve M., additional, Collette, Sabine L., additional, Groot, Adrien E. D., additional, LeCouffe, Natalie E., additional, Konduri, Praneeta R., additional, Prasetya, Haryadi, additional, Arrarte‐Terreros, Nerea, additional, and Ramos, Lucas A., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Health-related quality of life in Guillain-Barré syndrome patients: a systematic review
- Author
-
Darweesh, Sirwan K. L., Polinder, Suzanne, Mulder, Maxim J. H. L., Baena, Cristina P., van Leeuwen, Nikki, Franco, Oscar H., Jacobs, Bart C., and van Doorn, Pieter A.
- Published
- 2014
- Full Text
- View/download PDF
12. Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well: results from the MR CLEAN Registry
- Author
-
Dekker, Luuk, primary, Venema, Esmee, additional, Pirson, F Anne V, additional, Majoie, Charles B L M, additional, Emmer, Bart J, additional, Jansen, Ivo G H, additional, Mulder, Maxim J H L, additional, Lemmens, Robin, additional, Goldhoorn, Robert-Jan B, additional, Wermer, Marieke J H, additional, Boiten, Jelis, additional, Lycklama à Nijeholt, Geert J, additional, Roos, Yvo B W E M, additional, van Es, Adriaan C G M, additional, Lingsma, Hester F, additional, Dippel, Diederik W J, additional, van Zwam, Wim H, additional, van Oostenbrugge, Robert J, additional, and van den Wijngaard, Ido R, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Effect of First‐Pass Reperfusion on Outcome After Endovascular Treatment for Ischemic Stroke
- Author
-
den Hartog, Sanne J., primary, Zaidat, Osama, additional, Roozenbeek, Bob, additional, van Es, Adriaan C. G. M., additional, Bruggeman, Agnetha A. E., additional, Emmer, Bart J., additional, Majoie, Charles B. L. M., additional, van Zwam, Wim H., additional, van den Wijngaard, Ido R., additional, van Doormaal, Pieter Jan, additional, Lingsma, Hester F., additional, Burke, James F., additional, Dippel, Diederik W. J., additional, van der Lugt, Aad, additional, Roos, Yvo B. W. E. M., additional, van Oostenbrugge, Robert J., additional, Boiten, Jelis, additional, Vos, Jan Albert, additional, Jansen, Ivo G. H., additional, Mulder, Maxim J. H. L., additional, Goldhoorn, Robert‐Jan B., additional, Compagne, Kars C. J., additional, Kappelhof, Manon, additional, Brouwer, Josje, additional, Hinsenveld, Wouter H., additional, Coutinho, Jonathan M., additional, Schonewille, Wouter J., additional, Wermer, Marieke J. H., additional, van Walderveen, Marianne A. A., additional, Staals, Julie, additional, Hofmeijer, Jeannette, additional, Martens, Jasper M., additional, Lycklama à Nijeholt, Geert J., additional, de Bruijn, Sebastiaan F., additional, van Dijk, Lukas C., additional, van der Worp, H. Bart, additional, Lo, Rob H., additional, van Dijk, Ewoud J., additional, Boogaarts, Hieronymus D., additional, de Vries, J., additional, de Kort, Paul L. M., additional, van Tuijl, Julia, additional, Peluso, Jo P., additional, Fransen, Puck, additional, van den Berg, Jan S. P., additional, van Hasselt, Boudewijn A. A. M., additional, Aerden, Leo A. M., additional, Dallinga, René J., additional, Uyttenboogaart, Maarten, additional, Eschgi, Omid, additional, Bokkers, Reinoud P. H., additional, Schreuder, Tobien H. C. M. L., additional, Heijboer, Roel J. J., additional, Keizer, Koos, additional, Yo, Lonneke S. F., additional, den Hertog, Heleen M., additional, Sturm, Emiel J. C., additional, Brouwers, Paul J. A. M., additional, Sprengers, Marieke E. S., additional, Jenniskens, Sjoerd F. M., additional, van den Berg, René, additional, Yoo, Albert J., additional, Beenen, Ludo F. M., additional, Postma, Alida A., additional, Roosendaal, Stefan D., additional, van der Kallen, Bas F. W., additional, Bot, Joost, additional, Meijer, Anton, additional, Ghariq, Elyas, additional, van Proosdij, Marc P., additional, Krietemeijer, G. Menno, additional, Gerrits, Dick, additional, Dinkelaar, Wouter, additional, Appelman, Auke P. A., additional, Hammer, Bas, additional, Pegge, Sjoert, additional, van der Hoorn, Anouk, additional, Vinke, Saman, additional, Flach, H. Zwenneke, additional, el Ghannouti, Naziha, additional, Sterrenberg, Martin, additional, Pellikaan, Wilma, additional, Sprengers, Rita, additional, Elfrink, Marjan, additional, Simons, Michelle, additional, Vossers, Marjolein, additional, de Meris, Joke, additional, Vermeulen, Tamara, additional, Geerlings, Annet, additional, van Vemde, Gina, additional, Simons, Tiny, additional, Messchendorp, Gert, additional, Nicolaij, Nynke, additional, Bongenaar, Hester, additional, Bodde, Karin, additional, Kleijn, Sandra, additional, Lodico, Jasmijn, additional, Droste, Hanneke, additional, Wollaert, Maureen, additional, Verheesen, Sabrina, additional, Jeurrissen, D., additional, Bos, Erna, additional, Drabbe, Yvonne, additional, Sandiman, Michelle, additional, Aaldering, Nicoline, additional, Zweedijk, Berber, additional, Vervoort, Jocova, additional, Ponjee, Eva, additional, Romviel, Sharon, additional, Kanselaar, Karin, additional, Barning, Denn, additional, Venema, Esmee, additional, Chalos, Vicky, additional, Geuskens, Ralph R., additional, van Straaten, Tim, additional, Ergezen, Saliha, additional, Harmsma, Roger R. M., additional, Muijres, Daan, additional, de Jong, Anouk, additional, Berkhemer, Olvert A., additional, Boers, Anna M. M., additional, Huguet, J., additional, Groot, P. F. C., additional, Mens, Marieke A., additional, van Kranendonk, Katinka R., additional, Treurniet, Kilian M., additional, Tolhuisen, Manon L., additional, Alves, Heitor, additional, Weterings, Annick J., additional, Kirkels, Eleonora L. F., additional, Voogd, Eva J. H. F., additional, Schupp, Lieve M., additional, Collette, Sabine L., additional, Groot, Adrien E. D., additional, LeCouffe, Natalie E., additional, Konduri, Praneeta R., additional, Prasetya, Haryadi, additional, Arrarte‐Terreros, Nerea, additional, and Ramos, Lucas A., additional
- Published
- 2021
- Full Text
- View/download PDF
14. Improving quality of stroke care through benchmarking center performance: why focusing on outcomes is not enough
- Author
-
Amini, Marzyeh, van Leeuwen, Nikki, Eijkenaar, Frank, Mulder, Maxim J. H. L., Schonewille, Wouter, Nijeholt, Geert Lycklama a, Hinsenveld, Wouter H., Goldhoorn, Robert-Jan B., van Doormaal, Pieter Jan, Jenniskens, Sjoerd, Hazelzet, Jan, Dippel, Diederik W. J., Roozenbeek, Bob, Lingsma, Hester F., van Zwam, Wim, Clinical Neurophysiology, TechMed Centre, Radiology and Nuclear Medicine, ACS - Microcirculation, ANS - Neurovascular Disorders, Neurology, ACS - Atherosclerosis & ischemic syndromes, Graduate School, ACS - Pulmonary hypertension & thrombosis, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, ARD - Amsterdam Reproduction and Development, AMS - Amsterdam Movement Sciences, Biomedical Engineering and Physics, Adult Psychiatry, APH - Methodology, Public Health, Erasmus School of Health Policy & Management, Radiology & Nuclear Medicine, Klinische Neurowetenschappen, RS: Carim - B05 Cerebral small vessel disease, MUMC+: MA Niet Med Staf Neurologie (9), RS: Carim - B06 Imaging, Beeldvorming, MUMC+: DA BV Medisch Specialisten Radiologie (9), Radiology and nuclear medicine, Amsterdam Neuroscience - Neurovascular Disorders, Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)
- Subjects
Male ,Quality management ,Outcome (game theory) ,THERAPY ,Cohort Studies ,03 medical and health sciences ,GENERAL-ANESTHESIA ,0302 clinical medicine ,Case mix index ,All institutes and research themes of the Radboud University Medical Center ,CONSCIOUS SEDATION ,Modified Rankin Scale ,medicine ,IMPUTATION ,MANAGEMENT ,Case-mix ,Humans ,REPERFUSION ,Endovascular treatment ,030212 general & internal medicine ,ACUTE ISCHEMIC-STROKE ,Stroke ,Aged ,Aged, 80 and over ,business.industry ,Health Policy ,lcsh:Public aspects of medicine ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,Quality of care ,lcsh:RA1-1270 ,Middle Aged ,Random effects model ,medicine.disease ,Quality Improvement ,ENDOVASCULAR THROMBECTOMY ,Benchmarking ,Variation (linguistics) ,Treatment Outcome ,HOSPITAL VOLUME ,Outcome differences ,OF-CARE ,Process of care ,Female ,business ,030217 neurology & neurosurgery ,Demography ,Cohort study ,Research Article - Abstract
Background Between-center variation in outcome may offer opportunities to identify variation in quality of care. By intervening on these quality differences, patient outcomes may be improved. However, whether observed differences in outcome reflect the true quality improvement potential is not known for many diseases. Therefore, we aimed to analyze the effect of differences in performance on structure and processes of care, and case-mix on between-center differences in outcome after endovascular treatment (EVT) for ischemic stroke. Methods In this observational cohort study, ischemic stroke patients who received EVT between 2014 and 2017 in all 17 Dutch EVT-centers were included. Primary outcome was the modified Rankin Scale, ranging from 0 (no symptoms) to 6 (death), at 90 days. We used random effect proportional odds regression modelling, to analyze the effect of differences in structure indicators (center volume and year of admission), process indicators (time to treatment and use of general anesthesia) and case-mix, by tracking changes in tau2, which represents the amount of between-center variation in outcome. Results Three thousand two hundred seventy-nine patients were included. Performance on structure and process indicators varied significantly between EVT-centers (P tau2) was estimated at 0.040 in a model only accounting for random variation. This estimate more than doubled after adding case-mix variables (tau2: 0.086) to the model, while a small amount of between-center variation was explained by variation in performance on structure and process indicators (tau2: 0.081 and 0.089, respectively). This indicates that variation in case-mix affects the differences in outcome to a much larger extent. Conclusions Between-center variation in outcome of ischemic stroke patients mostly reflects differences in case-mix, rather than differences in structure or process of care. Since the latter two capture the real quality improvement potential, these should be used as indicators for comparing center performance. Especially when a strong association exists between those indicators and outcome, as is the case for time to treatment in ischemic stroke.
- Published
- 2020
- Full Text
- View/download PDF
15. Additional file 1 of Improving quality of stroke care through benchmarking center performance: why focusing on outcomes is not enough
- Author
-
Amini, Marzyeh, Leeuwen, Nikki Van, Eijkenaar, Frank, Mulder, Maxim J. H. L., Schonewille, Wouter, Nijeholt, Geert Lycklama, Hinsenveld, Wouter H., Robert-Jan B. Goldhoorn, Doormaal, Pieter Jan Van, Jenniskens, Sjoerd, Hazelzet, Jan, Dippel, Diederik W. J., Roozenbeek, Bob, and Lingsma, Hester F.
- Abstract
Additional file 1: Table S1. Case-mix characteristics of patients treated in intervention centers in the MR CLEAN Registry. Table S2. Quality of care indicators characteristics of the intervention centers in the MR CLEAN Registry database. Figure S1. Specialized EVT centers in the Netherlands. Adapted from MR CLEAN Registry study ( https://www.mrclean-trial.org/mr-clean-registry/participating-centers.html ). Figure S2. Flowchart of patient selection in the MR CLEAN Registry. Figure S3 Forest plot reporting odds ratios with 95% confidence intervals of the fixed effects of the case-mix variables on the inverse of the modified Rankin Scale at 90 days using random effect proportional odds regression analysis in the case-mix adjusted model.
- Published
- 2020
- Full Text
- View/download PDF
16. National Institutes of Health Stroke Scale: An Alternative Primary Outcome Measure for Trials of Acute Treatment for Ischemic Stroke
- Author
-
Chalos, Vicky, van der Ende, Nadinda A. M., Lingsma, Hester F., Mulder, Maxim J. H. L., Venema, Esmee, Dijkland, Simone A., Berkhemer, Olvert A., Yoo, Albert J., Broderick, Joseph P., Palesch, Yuko Y., Yeatts, Sharon D., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Majoie, Charles B. L. M., van der Lugt, Aad, Roozenbeek, Bob, Dippel, Diederik W. J., Fransen, Puck S. S., Beumer, Debbie, van den Berg, Lucie A., Schonewille, Wouter J., Vos, Jan Albert, Nederkoorn, Paul J., Wermer, Marieke J. H., van Walderveen, Marianne A. A., Staals, Julie, Hofmeijer, Jeannette, van Oostayen, Jacques A., Nijeholt, Geert J. Lycklama A., Boiten, Jelis, Brouwer, Patrick A., Emmer, Bart J., de Bruijn, Sebastiaan F., van Dijk, Lukas C., Kappelle, L. Jaap, Lo, Rob H., van Dijk, Ewoud J., de Vries, Joost, de Kort, Paul L. M., van Rooij, Willem Jan J., van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, Rene J., Visser, Marieke C., Bot, Joseph C. J., Vroomen, Patrick C., Eshghi, Omid, Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Keizer, Koos, Tielbeek, Alexander V., den Hertog, Heleen M., Gerrits, Dick G., van den Berg-Vos, Renske M., Karas, Giorgos B., Steyerberg, Ewout W., Flach, H. Zwenneke, Marquering, Henk A., Sprengers, Marieke E. S., Jenniskens, Sjoerd F. M., Beenen, Ludo F. M., van den Berg, Rene, Koudstaal, Peter J., Radiology and nuclear medicine, VU University medical center, Neurology, Amsterdam Neuroscience - Neurovascular Disorders, ACS - Atherosclerosis & ischemic syndromes, Public Health, Radiology & Nuclear Medicine, Radiology and Nuclear Medicine, ANS - Neurovascular Disorders, ACS - Microcirculation, ACS - Amsterdam Cardiovascular Sciences, Graduate School, ACS - Pulmonary hypertension & thrombosis, AGEM - Digestive immunity, AGEM - Re-generation and cancer of the digestive system, ARD - Amsterdam Reproduction and Development, MUMC+: MA Neurologie (3), Klinische Neurowetenschappen, MUMC+: Hersen en Zenuw Centrum (3), RS: Carim - B05 Cerebral small vessel disease, Beeldvorming, MUMC+: DA BV Medisch Specialisten Radiologie (9), RS: Carim - B06 Imaging, MUMC+: MA AIOS Neurologie (9), and MUMC+: MA Med Staf Spec Neurologie (9)
- Subjects
Male ,endovascular treatment ,Original Contributions ,030204 cardiovascular system & hematology ,law.invention ,Brain Ischemia ,0302 clinical medicine ,Randomized controlled trial ,Modified Rankin Scale ,Informed consent ,law ,Stroke ,Netherlands ,Confounding ,Endovascular Procedures ,informed consent ,Middle Aged ,Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] ,stroke ,3. Good health ,thrombectomy ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,outcome ,Female ,Cardiology and Cardiovascular Medicine ,SURROGATE END-POINTS ,CLINICAL-TRIALS ,medicine.medical_specialty ,Mechanical Thrombolysis ,ENDOVASCULAR THERAPY ,Clinical Sciences ,03 medical and health sciences ,ALTEPLASE ,Internal medicine ,medicine ,Humans ,cardiovascular diseases ,PLASMINOGEN-ACTIVATOR ,Aged ,Advanced and Specialized Nursing ,Surrogate endpoint ,business.industry ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,Odds ratio ,medicine.disease ,United States ,RANDOMIZED-TRIAL ,Clinical trial ,SEVERITY ,National Institutes of Health (U.S.) ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Follow-Up Studies ,NIHSS - Abstract
Supplemental Digital Content is available in the text., Background and Purpose— The modified Rankin Scale (mRS) at 3 months is the most commonly used primary outcome measure in stroke treatment trials, but it lacks specificity and requires long-term follow-up interviews, which consume time and resources. An alternative may be the National Institutes of Health Stroke Scale (NIHSS), early after stroke. Our aim was to evaluate whether the NIHSS assessed within 1 week after treatment could serve as a primary outcome measure for trials of acute treatment for ischemic stroke. Methods— We used data from 2 randomized controlled trials of endovascular treatment for ischemic stroke: the positive MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; N=500) and the neutral IMS (Interventional Management of Stroke) III trial (N=656). We used a causal mediation model, with linear and ordinal logistic regression adjusted for confounders, to evaluate the NIHSS 24 hours and 5 to 7 days after endovascular treatment as primary outcome measures (instead of the mRS at 3 months) in both trials. Patients who had died before the NIHSS was assessed received the maximum score of 42. NIHSS+1 was then log10-transformed. Results— In both trials, there was a significant correlation between the NIHSS at 24 hours and 5 to 7 days and the mRS. In MR CLEAN, we found a significant effect of endovascular treatment on the mRS and on the NIHSS at 24 hours and 5 to 7 days. After adjustment for NIHSS at 24 hours and 5 to 7 days, the effect of endovascular treatment on the mRS decreased from common odds ratio 1.68 (95% CI, 1.22–2.32) to respectively 1.36 (95% CI, 0.97–1.91) and 1.24 (95% CI, 0.87–1.79), indicating that treatment effect on the mRS is in large part mediated by the NIHSS. In the IMS III trial there was no treatment effect on the NIHSS at 24 hours and 5 to 7 days, corresponding with the absence of a treatment effect on the mRS. Conclusions— The NIHSS within 1 week satisfies the requirements for a surrogate end point and may be used as a primary outcome measure in trials of acute treatment for ischemic stroke, particularly in phase II(b) trials. This could reduce stroke-outcome assessment to its essentials (ie, neurological deficit), and reduce trial duration and costs. Whether and under which conditions it could be used in phase III trials requires a debate in the field with all parties. Clinical Trial Registration— URL: http://www.isrctn.com. Unique identifier: ISRCTN10888758; https://www.clinicaltrials.gov. Unique identifier: NCT00359424.
- Published
- 2020
- Full Text
- View/download PDF
17. Quantified health and cost effects of faster endovascular treatment for large vessel ischemic stroke patients in the Netherlands
- Author
-
van Voorst, Henk, primary, Kunz, Wolfgang G, additional, van den Berg, Lucie A, additional, Kappelhof, Manon, additional, Pinckaers, Floor M E, additional, Goyal, Mayank, additional, Hunink, Myriam G M, additional, Emmer, Bart J, additional, Mulder, Maxim J H L, additional, Dippel, Diederik W J, additional, Coutinho, Jonathan M, additional, Marquering, Henk A, additional, Boogaarts, Hieronymus D, additional, van der Lugt, Aad, additional, van Zwam, Wim H, additional, Roos, Yvo B W E M, additional, Buskens, Erik, additional, Dijkgraaf, Marcel G W, additional, and Majoie, Charles B L M, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Safety and Outcome of Endovascular Treatment for Minor Ischemic Stroke: Results From the Multicenter Clinical Registry of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands
- Author
-
Goldhoorn, Robert-Jan B., Mulder, Maxim J. H. L., Jansen, Ivo G. H., van Zwam, Wim H., Staals, Julie, van der Lugt, Aad, Dippel, Diederik W. J., Lingsma, Hester F., Vos, Jan Albert, Boiten, Jelis, van den Wijngaard, Ido R., Majoie, Charles B. L. M., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., Schonewille, Wouter J., Coutinho, Jonathan M., Wermer, Marieke J. H., van Walderveen, Marianne A. A., Hofmeijer, Jeannette, Martens, Jasper M., Nijeholt, Geert J. Lycklama A., Roozenbeek, Bob, Emmer, Bart J., de Bruijn, Sebastiaan F., van Dijk, Lukas C., van der Worp, H. Bart, Lo, Rob H., van Dijk, Ewoud J., Boogaarts, Hieronymus D., de Kort, Paul L. M., Peluso, Jo J. P., van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, Rene J., Uyttenboogaart, Maarten, Eshghi, Omid, Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Keizer, Koos, Yo, Lonneke S. F., den Hertog, Heleen M., Sturm, Emiel J. C., Sprengers, Marieke E. S., Jenniskens, Sjoerd F. M., Postma, Alida, Hinsenveld, Wouter, Groot, P. F. C., MR CLEAN Registry Investigators, Goldhoorn, Robert-Jan B., Mulder, Maxim J. H. L., Jansen, Ivo G. H., van Zwam, Wim H., Staals, Julie, van der Lugt, Aad, Dippel, Diederik W. J., Lingsma, Hester F., Vos, Jan Albert, Boiten, Jelis, van den Wijngaard, Ido R., Majoie, Charles B. L. M., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., Schonewille, Wouter J., Coutinho, Jonathan M., Wermer, Marieke J. H., van Walderveen, Marianne A. A., Hofmeijer, Jeannette, Martens, Jasper M., Nijeholt, Geert J. Lycklama A., Roozenbeek, Bob, Emmer, Bart J., de Bruijn, Sebastiaan F., van Dijk, Lukas C., van der Worp, H. Bart, Lo, Rob H., van Dijk, Ewoud J., Boogaarts, Hieronymus D., de Kort, Paul L. M., Peluso, Jo J. P., van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, Rene J., Uyttenboogaart, Maarten, Eshghi, Omid, Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Keizer, Koos, Yo, Lonneke S. F., den Hertog, Heleen M., Sturm, Emiel J. C., Sprengers, Marieke E. S., Jenniskens, Sjoerd F. M., Postma, Alida, Hinsenveld, Wouter, Groot, P. F. C., and MR CLEAN Registry Investigators
- Abstract
Goal: Insufficient data is available about safety and efficacy of endovascular treatment (EVT) in patients with minor stroke symptoms because these patients were excluded from most randomized trials. We aimed to compare characteristics, functional outcome, and complications in patients with minor ischemic stroke National Institutes of Health Stroke Scale score = 6) due to intracranial proximal artery occlusion of the anterior circulation who underwent EVT. Materials and Methods: We report patients with an anterior circulation occlusion who were included between March 2014 and June 2016 in the multicenter randomized clinical trial of EVT of acute ischemic stroke in the Netherlands Registry, a prospective, multicenter, observational study for stroke centers that perform EVT in the Netherlands. Minor ischemic stroke was defined as baseline NIHSS score of 5 or less. Primary outcome is the modified Rankin Scale (mRS) score at 90 days. Secondary outcomes include symptomatic intracranial hemorrhage (sICH) and mortality. Findings: Seventy-one (5.5%) patients had a NIHSS score of 5 or less. Functional independence (mRS 0-2 at 90 days) was reached in 75% of these patients, compared to 40% of patients with NIHSS score of 6 or more. sICH occurred in 4% of patients, of which 1% occurred peri-interventionally. Death occurred in 6% of patients. Conclusions: Patients with minor ischemic stroke with an intracranial proximal arterial occlusion of the anterior circulation who underwent EVT have a high chance of favorable outcome and appear to have low occurrence of treatment-related sICH. Therefore, our results encourage the use of EVT for minor ischemic stroke in the absence of effect estimates from controlled studies.
- Published
- 2019
19. Impact of single phase CT angiography collateral status on functional outcome over time: results from the MR CLEAN Registry
- Author
-
Jansen, Ivo G. H., Mulder, Maxim J. H. L., Goldhoorn, Robert-Jan B., Boers, Anna M. M., van Es, Adriaan C. G. M., Yo, Lonneke S. F., Hofmeijer, Jeannette, Martens, Jasper M., van Walderveen, Marianne A. A., van der Kallen, Bas F. W., Jenniskens, Sjoerd F. M., Treurniet, Kilian M., Marqueriny, Henk A., Sprengers, Marieke E. S., Schonewille, Wouter J., Bot, Joost, Lycklama A Nijeholt, Geert J., Lingsma, Hester F., Liebeskind, David S., Boiten, Jelis, Vos, Jan-Albert, Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van der Lugt, Aad, van Zwam, Wim H., Dippel, Diederik W. J., van den Wijngaard, Ido R., Majoie, Charles B. L. M., Coutinho, Jonathan M., Wermern, Marieke J. H., Staals, Julie, Roozenbeek, Bob, Emmer, Bart J., de Bruijn, Sebastiaan F., van Dijk, Lukas C., van der Worp, H. Bart, Lo, Rob H., van Dijk, Ewoud J., Boogaarts, Hieronymus D., de Kort, Paul L. M., Peluso, Jo J. P., van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, Rene J., Uyttenboogaart, Maarten, Eshghi, Omid, Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Groot, P. F. C., MR CLEAN Registry Investigators, Jansen, Ivo G. H., Mulder, Maxim J. H. L., Goldhoorn, Robert-Jan B., Boers, Anna M. M., van Es, Adriaan C. G. M., Yo, Lonneke S. F., Hofmeijer, Jeannette, Martens, Jasper M., van Walderveen, Marianne A. A., van der Kallen, Bas F. W., Jenniskens, Sjoerd F. M., Treurniet, Kilian M., Marqueriny, Henk A., Sprengers, Marieke E. S., Schonewille, Wouter J., Bot, Joost, Lycklama A Nijeholt, Geert J., Lingsma, Hester F., Liebeskind, David S., Boiten, Jelis, Vos, Jan-Albert, Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van der Lugt, Aad, van Zwam, Wim H., Dippel, Diederik W. J., van den Wijngaard, Ido R., Majoie, Charles B. L. M., Coutinho, Jonathan M., Wermern, Marieke J. H., Staals, Julie, Roozenbeek, Bob, Emmer, Bart J., de Bruijn, Sebastiaan F., van Dijk, Lukas C., van der Worp, H. Bart, Lo, Rob H., van Dijk, Ewoud J., Boogaarts, Hieronymus D., de Kort, Paul L. M., Peluso, Jo J. P., van den Berg, Jan S. P., van Hasselt, Boudewijn A. A. M., Aerden, Leo A. M., Dallinga, Rene J., Uyttenboogaart, Maarten, Eshghi, Omid, Schreuder, Tobien H. C. M. L., Heijboer, Roel J. J., Groot, P. F. C., and MR CLEAN Registry Investigators
- Abstract
Background Collateral status modified the effect of endovascular treatment (EVT) for stroke in several randomized trials. We assessed the association between collaterals and functional outcome in EVT treated patients and investigated if this association is time dependent.Methods We included consecutive patients from the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands (MR CLEAN) Registry (March 2014-June 2016) with an anterior circulation large vessel occlusion undergoing EVT. Functional outcome was measured on the modified Rankin Scale (mRS) at 90 days. We investigated the association between collaterals and mRS in the MR CLEAN Registry with ordinal logistic regression and if this association was time dependent with an interaction term. Additionally, we determined modification of EVT effect by collaterals compared with MR CLEAN controls, and also investigated if this was time dependent with multiplicative interaction terms.Results 1412 patients were analyzed. Functional independence (mRS score of 0-2) was achieved in 13% of patients with grade 0 collaterals, in 27% with grade 1, in 46% with grade 2, and in 53% with grade 3. Collaterals were significantly associated with mRS (adjusted common OR 1.5 (95% CI 1.4 to 1.7)) and significantly modified EVT benefit (P=0.04). None of the effects were time dependent. Better collaterals corresponded to lower mortality (PConclusion In routine clinical practice, better collateral status is associated with better functional outcome and greater treatment benefit in EVT treated acute ischemic stroke patients, independent of time to treatment. Within the 6 hour time window, a substantial proportion of patients with absent and poor collaterals can still achieve functional independence.
- Published
- 2019
20. Prediction of Outcome and Endovascular Treatment Benefit: Validation and Update of the MR PREDICTS Decision Tool.
- Author
-
Venema, Esmee, Roozenbeek, Bob, Mulder, Maxim J. H. L., Brown, Scott, Majoie, Charles B. L. M., Steyerberg, Ewout W., Demchuk, Andrew M., Muir, Keith W., Dávalos, Antoni, Mitchell, Peter J., Bracard, Serge, Berkhemer, Olvert A., Nijeholt, Geert J. Lycklama À., van Oostenbrugge, Robert J., Roos, Yvo B. W. E. M., van Zwam, Wim H., van der Lugt, Aad, Hill, Michael D., White, Philip, and Campbell, Bruce C. V.
- Published
- 2021
- Full Text
- View/download PDF
21. Endovascular Treatment With or Without Prior Intravenous Alteplase for Acute Ischemic Stroke
- Author
-
Chalos, Vicky, primary, LeCouffe, Natalie E., additional, Uyttenboogaart, Maarten, additional, Lingsma, Hester F., additional, Mulder, Maxim J. H. L., additional, Venema, Esmee, additional, Treurniet, Kilian M., additional, Eshghi, Omid, additional, van der Worp, H. Bart, additional, van der Lugt, Aad, additional, Roos, Yvo B. W. E. M., additional, Majoie, Charles B. L. M., additional, Dippel, Diederik W. J., additional, Roozenbeek, Bob, additional, Coutinho, Jonathan M., additional, van Oostenbrugge, Robert J., additional, van Zwam, Wim H., additional, Boiten, Jelis, additional, Vos, Jan Albert, additional, Jansen, Ivo G. H., additional, Goldhoorn, Robert‐Jan B., additional, Schonewille, Wouter J., additional, Wermer, Marieke J. H., additional, van Walderveen, Marianne A. A., additional, Staals, Julie, additional, Hofmeijer, Jeannette, additional, Martens, Jasper M., additional, Lycklama à Nijeholt, Geert J., additional, Emmer, Bart J., additional, de Bruijn, Sebastiaan F., additional, van Dijk, Lukas C., additional, Lo, Rob H., additional, van Dijk, Ewoud J., additional, Boogaarts, Hieronymus D., additional, de Kort, Paul L. M., additional, Peluso, Jo J. P., additional, van den Berg, Jan S. P., additional, van Hasselt, Boudewijn A. A. M., additional, Aerden, Leo A. M., additional, Dallinga, René J., additional, Schreuder, Tobien H. C. M. L., additional, Heijboer, Roel J. J., additional, Keizer, Koos, additional, Yo, Lonneke S. F., additional, den Hertog, Heleen M., additional, Sturm, Emiel J. C., additional, Sprengers, Marieke E. S., additional, Jenniskens, Sjoerd F. M., additional, van den Berg, René, additional, Yoo, Albert J., additional, Beenen, Ludo F. M., additional, Roosendaal, Stefan D., additional, van der Kallen, Bas F. W., additional, van den Wijngaard, Ido R., additional, van Es, Adriaan C. G. M., additional, Bot, Joseph C. J., additional, van Doormaal, Pieter‐Jan, additional, Flach, H. Zwenneke, additional, el Ghannouti, Naziha, additional, Sterrenberg, Martin, additional, Puppels, Corina, additional, Pellikaan, Wilma, additional, Sprengers, Rita, additional, Elfrink, Marjan, additional, de Meris, Joke, additional, Vermeulen, Tamara, additional, Geerlings, Annet, additional, van Vemde, Gina, additional, Simons, Tiny, additional, van Rijswijk, Cathelijn, additional, Messchendorp, Gert, additional, Bongenaar, Hester, additional, Bodde, Karin, additional, Kleijn, Sandra, additional, Lodico, Jasmijn, additional, Droste, Hanneke, additional, Wollaert, M., additional, Jeurrissen, D., additional, Bos, Ernas, additional, Drabbe, Yvonne, additional, Zweedijk, Berber, additional, Khalilzada, Mostafa, additional, Compagne, Kars C. J., additional, Geuskens, Ralph R., additional, van Straaten, Tim, additional, Ergezen, Saliha, additional, Harmsma, Roger R. M., additional, de Jong, Anouk, additional, Hinsenveld, Wouter, additional, Berkhemer, Olvert A., additional, Boers, Anna M. M., additional, Groot, P. F. C., additional, Mens, Marieke A., additional, van Kranendonk, Katinka R., additional, Kappelhof, Manon, additional, Tolhuijsen, Manon L., additional, and Alves, Heitor, additional
- Published
- 2019
- Full Text
- View/download PDF
22. Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials
- Author
-
Venema, Esmee, primary, Mulder, Maxim J H L, additional, Roozenbeek, Bob, additional, Broderick, Joseph P, additional, Yeatts, Sharon D, additional, Khatri, Pooja, additional, Berkhemer, Olvert A, additional, Emmer, Bart J, additional, Roos, Yvo B W E M, additional, Majoie, Charles B L M, additional, van Oostenbrugge, Robert J, additional, van Zwam, Wim H, additional, van der Lugt, Aad, additional, Steyerberg, Ewout W, additional, Dippel, Diederik W J, additional, and Lingsma, Hester F, additional
- Published
- 2017
- Full Text
- View/download PDF
23. Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid
- Author
-
Mulder, Maxim J H L, primary, Venema, Esmee, additional, Roozenbeek, Bob, additional, Broderick, Joseph P, additional, Yeatts, Sharon D, additional, Khatri, Pooja, additional, Berkhemer, Olvert A, additional, Roos, Yvo B W E M, additional, Majoie, Charles B L M, additional, van Oostenbrugge, Robert J, additional, van Zwam, Wim H, additional, van der Lugt, Aad, additional, Steyerberg, Ewout W, additional, Dippel, Diederik W J, additional, and Lingsma, Hester F, additional
- Published
- 2017
- Full Text
- View/download PDF
24. Persistent orofacial muscle pain: Its synonymous terminology and presentation
- Author
-
Spierings, Egilius L. H., primary and Mulder, Maxim J. H. L., additional
- Published
- 2016
- Full Text
- View/download PDF
25. Occurrence of intracranial large vessel occlusion in consecutive, non-referred patients with acute ischemic stroke
- Author
-
Beumer, Debbie, primary, Mulder, Maxim J. H. L., additional, Saiedie, Ghesrouw, additional, Fonville, Susanne, additional, van Oostenbrugge, Robert J., additional, van Zwam, Wim H., additional, Homburg, Philip J., additional, van der Lugt, Aad, additional, and Dippel, Diederik W. J., additional
- Published
- 2016
- Full Text
- View/download PDF
26. Conscious sedation or local anesthesia during endovascular treatment for acute ischemic stroke.
- Author
-
van de Graaf, Rob A., Samuels, Noor, Mulder, Maxim J. H. L., Eralp, Ismail, van Es, Adriaan C. G. M., Dippel, Diederik W. J., van der Lugt, Aad, Emmer, Bart J., and Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) Registry Investigators
- Published
- 2018
- Full Text
- View/download PDF
27. Persistent orofacial muscle pain: Its synonymous terminology and presentation.
- Author
-
Spierings, Egilius L. H. and Mulder, Maxim J. H. L.
- Subjects
OROFACIAL pain ,MASSETER muscle ,MASTICATION ,DEMOGRAPHY ,CHI-squared test - Abstract
Objective: The purpose of the present paper is to describe the presentation of persistent orofacial muscle pain, also commonly referred to as myofascial temporomandibular disorder.Methods: In this practice survey, the authors reviewed the demographic and clinical features of 34 patients who were evaluated and diagnosed personally.Results: The majority of the 34 patients were women (82.4%), and their age at consultation averaged 44.6 ± 12.6 (SD) years. The median pain duration was 4.0 years (range: 0.2-34 years). In 97.1% of patients, the pain occurred daily and continuously, and in 51.9% it was unilateral. Chewing or eating made the pain worse in 50% of the patients, and talking in 29.4%. On examination, tightness of the masseter muscle(s) was present in 58.8%, and tenderness in 58.8%.Conclusions: Persistent orofacial muscle pain mostly affects women, generally occurs daily and continuously, and is equally often unilateral and bilateral. Chewing, eating, and talking are the most common aggravating factors, and tightness or tenderness of the masseter muscle(s) is often found on examination. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. Baseline Blood Pressure Effect on the Benefit and Safety of Intra-Arterial Treatment in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands).
- Author
-
Mulder, Maxim J. H. L., Ergezen, Saliha, Lingsma, Hester F., Berkhemer, Olvert A., Fransen, Puck S. S., Beumer, Debbie, van den Berg, Lucie A., Lycklama à Nijeholt, Geert, Emmer, Bart J., van der Worp, H. Bart, Nederkoorn, Paul J., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Majoie, Charles B. L. M., van der Lugt, Aad, Dippel, Diederik W. J., Lycklama À Nijeholt, Geert, and Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) Investigators
- Published
- 2017
- Full Text
- View/download PDF
29. Does prior antiplatelet treatment improve functional outcome after intra-arterial treatment for acute ischemic stroke?
- Author
-
Mulder, Maxim J. H. L., Berkhemer, Olvert A., Fransen, Puck S. S., van den Berg, Lucie A., Lingsma, Hester F., den Hertog, Heleen M., Staals, Julie, Jenniskens, Sjoerd F. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Majoie, Charles B. L. M., van der Lugt, Aad, and Dippel, Diederik W. J.
- Subjects
- *
PLATELET aggregation inhibitors , *CEREBRAL ischemia , *TREATMENT effectiveness , *REPERFUSION , *LOGISTIC regression analysis - Abstract
Background and purpose: In patients with acute ischemic stroke who receive antiplatelet treatment, uncertainty exists about the effect and safety of intra-arterial treatment. Our aim was to study whether intra-arterial treatment in patients with prior antiplatelet treatment is safe and whether prior antiplatelet treatment modifies treatment effect. Methods: All 500 MR CLEAN patients were included. We estimated the effect of intra-arterial treatment with ordinal logistic regression analysis, and tested for interaction of antiplatelet treatment with intra-arterial treatment on outcome. Furthermore, safety parameters and serious adverse events were analyzed. Results: The 144 patients (29%) on antiplatelet treatment were older, more often male, and had more vascular comorbidity. Intra-arterial treatment effect size after adjustments in antiplatelet treatment patients was 1.7 (95% confidence interval 0.9-3.2), and in no antiplatelet treatment patients 1.8 (95% confidence interval: 1.2-2.6). There was no statistically or clinically significant interaction between prior antiplatelet treatment and the relative effect of intra-arterial treatment (p=0.78). However, in patients on antiplatelet treatment, the effect of successful reperfusion on functional outcome in the intervention arm of the trial was doubled: the absolute risk difference for favorable outcome after successful reperfusion in patients on prior antiplatelet treatment was 39% versus 18% in patients not on prior antiplatelet treatment (Pinteraction=0.025). Patients on antiplatelet treatment more frequently had a symptomatic intracranial hemorrhage (15%) compared to patients without antiplatelet treatment (4%), without differences between the control and intervention arm. Conclusions: Prior treatment with antiplatelet agents did not modify the effect of intra-arterial treatment in patients with acute ischemic stroke presenting with an intracranial large vessel occlusion. There were no safety concerns. In patients with reperfusion, antiplatelet agents may improve functional outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Treatment in patients who are not eligible for intravenous alteplase: MR CLEAN subgroup analysis.
- Author
-
Mulder, Maxim J. H. L., Berkhemer, Olvert A., Fransen, Puck S. S., Beumer, Debbie, van den Berg, Lucie A., Lingsma, Hester F., Roos, Yvo B. W. E. M., van Oostenbrugge, Robert J., van Zwam, Wim H., Majoie, Charles B. L. M., van der Lugt, Aad, and Dippel, Diederik W. J.
- Subjects
- *
STROKE patients , *INTRA-arterial infusions , *TISSUE plasminogen activator , *INTRAVENOUS therapy , *ATRIAL fibrillation treatment , *SURGICAL stents , *THROMBOLYTIC therapy , *THERAPEUTICS - Abstract
Background and purpose: Patients with acute ischemic stroke due to intracranial large vessel occlusion benefit from intra-arterial therapy. Uncertainty exists about the effect of intra-arterial therapy in patients with contraindications for treatment with intravenous alteplase treatment. Our aim was to describe the clinical characteristics of this subgroup of patients and whether intra-arterial therapy is as safe and effective as it is after intravenous alteplase treatment. Methods: All 500 MR CLEAN patients were included and we distinguished between patients who were and were not treated with intravenous alteplase treatment. We estimated the effect of intra-arterial therapy on the shift on the modified Rankin Scale score with ordinal logistic regression analysis and tested for interaction of intravenous alteplase treatment with intra-arterial therapy on outcome. Furthermore, safety parameters and serious adverse events were analyzed. Results: Fifty-five patients (11%) were not treated with intravenous alteplase treatment, mostly because of prolonged coagulation time tests or recent surgery. These patients were older and more often had atrial fibrillation or other vascular comorbidity. There was no interaction between intravenous alteplase treatment and intervention effect (p=0.927). Intra-arterial therapy effect size in patients without intravenous alteplase treatment was 2.06 [95% CI: 0.69–6.13] and in patients with intravenous alteplase treatment 1.71 [95% CI: 1.22–2.40]. There were no safety issues. Conclusions: For patients with acute ischemic anterior circulation stroke caused by intracranial large vessel occlusion, who have contraindications for intravenous alteplase, intra-arterial treatment is not less effective or less safe than in patients who receive the treatment after intravenous alteplase. Clinical trial registration: Clinical trial registration-URL: http://www.trialregister.nl. Unique identifier: (NTR)1804. Clinical trial registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN10888758. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Response by Mulder et al to Letter Regarding Article, "Baseline Blood Pressure Effect on the Benefit and Safety of Intra-Arterial Treatment in MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the...
- Author
-
Mulder, Maxim J. H. L., Lingsma, Hester F., Dippel, Diederik W. J., and Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) Investigators
- Published
- 2017
- Full Text
- View/download PDF
32. Letter by Venema et al Regarding Article, "Validating a Predictive Model of Acute Advanced Imaging Biomarkers in Ischemic Stroke".
- Author
-
Venema, Esmee, Mulder, Maxim J. H. L., and Lingsma, Hester F.
- Published
- 2017
- Full Text
- View/download PDF
33. Letter by Mulder et al Regarding Article, "2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American...
- Author
-
Mulder, Maxim J. H. L., van Oostenbrugge, Robert J., Dippel, Diederik W. J., and MR CLEAN Investigators
- Published
- 2015
- Full Text
- View/download PDF
34. Endovascular treatment for acute ischaemic stroke in routine clinical practice : prospective, observational cohort study (MR CLEAN Registry)
- Author
-
MR CLEAN Registry investigators, Jansen, Ivo G H, Mulder, Maxim J H L, and Goldhoorn, Robert-Jan B
35. Selection of patients for intra-arterial treatment for acute ischaemic stroke : development and validation of a clinical decision tool in two randomised trials
- Author
-
Venema, Esmee, Mulder, Maxim J H L, Roozenbeek, Bob, Broderick, Joseph P, Yeatts, Sharon D, Khatri, Pooja, Berkhemer, Olvert A, Emmer, Bart J, Roos, Yvo B W E M, Majoie, Charles B L M, van Oostenbrugge, Robert J, van Zwam, Wim H, van der Lugt, Aad, Steyerberg, Ewout W, Dippel, Diederik W J, and Lingsma, Hester F
36. Use of diagnostic subtraction angiography for ischemic stroke (US DUTCH study) Regional variation and time-trend among medicare beneficiaries.
- Author
-
Mulder MJHL, Dippel DWJ, and Burke J
- Abstract
Introduction: There are no guideline recommendations for DSA in the ischemic stroke work-up. We studied the rate of DSA in ischemic stroke, the recent time-trend, hospital variation and associated factors., Methods: This is a retrospective cross-sectional study among Medicare fee-for-service beneficiaries with ischemic stroke admitted between 2016 and 2020 in the United States. ICD-10 codes were used to determine ischemic stroke diagnosis and procedure codes for thrombectomy and DSA. Hospital trends and factors associated with DSA performance were analyzed in hospitals with DSA capacity., Results: 7.373 (0.7%) of the 1,085,644 ischemic stroke patients, had a DSA for diagnostic purposes. In the patients that were admitted to a hospital with DSA facility, the following factors showed the strongest association with DSA: younger age (aOR=0.81 [95% confidence interval (CI):0.81-0.83]), thrombectomy rate in that hospital (aOR=2549 [95%CI:610-10663]), transfer (aOR=1.41[95%CI:1.34-1.50]) and carotid disease (aOR=5.8 [95%CI:5.6-6.1]). There was large variation in the hospital DSA rate, varying from 0.07% to 11.1%. Of the variance of DSA rates, 15% was attributed to the residual effect hospital propensity to perform DSA. The top decile of hospitals with the highest DSA rate, performed DSA's in >2.3% of patients, compared to the 0.6% median. There was no change in DSA rates over time., Conclusion: DSA is used infrequently in acute ischemic stroke patients and did not change between 2016 to 2020. Hospital variation in DSA use was however large, and not solely explained by patient and facility factors., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
37. Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy.
- Author
-
Bastiaansen AEM, de Bruijn MAAM, Schuller SL, Martinez-Hernandez E, Brenner J, Paunovic M, Crijnen YS, Mulder MJHL, Schreurs MWJ, de Graaff E, Smitt PAE, Neuteboom RF, de Vries JM, and Titulaer MJ
- Subjects
- Adolescent, Adult, Age of Onset, Aged, Aged, 80 and over, Anti-N-Methyl-D-Aspartate Receptor Encephalitis blood, Anti-N-Methyl-D-Aspartate Receptor Encephalitis cerebrospinal fluid, Anti-N-Methyl-D-Aspartate Receptor Encephalitis epidemiology, Child, Child, Preschool, Cohort Studies, Female, Humans, Infant, Male, Middle Aged, Netherlands epidemiology, Young Adult, Anti-N-Methyl-D-Aspartate Receptor Encephalitis diagnosis, Autoantibodies blood, Autoantibodies cerebrospinal fluid, Neoplasms epidemiology
- Abstract
Background and Objectives: To describe the clinical features of anti-NMDAR encephalitis, emphasizing on late-onset patients and antibody test characteristics in serum and CSF., Methods: Nationwide observational Dutch cohort study, in patients diagnosed with anti-NMDAR encephalitis between 2007 and 2019., Results: One hundred twenty-six patients with anti-NMDAR encephalitis were included with a median age of 24 years (range 1-86 years). The mean annual incidence was 1.00/million (95% CI 0.62-1.59). Patients ≥45 years of age at onset (19%) had fewer seizures (46% vs 71%, p = 0.021), fewer symptoms during disease course (3 vs 6 symptoms, p = 0.020), and more often undetectable serum antibodies compared with younger patients ( p = 0.031). In the late-onset group, outcome was worse, and all tumors were carcinomas (both p < 0.0001). CSF was more accurate than serum to detect anti-NMDAR encephalitis (sensitivity 99% vs 68%, p < 0.0001). Using cell-based assay (CBA), CSF provided an unconfirmed positive test result in 11/2,600 patients (0.4%); 6/11 had a neuroinflammatory disease (other than anti-NMDAR encephalitis). Patients with anti-NMDAR encephalitis, who tested positive in CSF only, had lower CSF antibody titers ( p = 0.003), but appeared to have an equally severe disease course., Discussion: Anti-NMDAR encephalitis occurs at all ages and is less rare in the elderly patients than initially anticipated. In older patients, the clinical phenotype is less outspoken, has different tumor association, and a less favorable recovery. Detection of antibodies in CSF is the gold standard, and although the CBA has very good validity, it is not perfect. The clinical phenotype should be leading, and confirmation in a research laboratory is recommended, when in doubt., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
- Published
- 2021
- Full Text
- View/download PDF
38. Admission Blood Pressure in Relation to Clinical Outcomes and Successful Reperfusion After Endovascular Stroke Treatment.
- Author
-
van den Berg SA, Uniken Venema SM, Mulder MJHL, Treurniet KM, Samuels N, Lingsma HF, Goldhoorn RB, Jansen IGH, Coutinho JM, Roozenbeek B, Dippel DWJ, Roos YBWEM, van der Worp HB, and Nederkoorn PJ
- Subjects
- Aged, Aged, 80 and over, Female, Functional Status, Hospitalization, Humans, Intracranial Hemorrhages physiopathology, Ischemic Stroke physiopathology, Linear Models, Logistic Models, Male, Middle Aged, Multivariate Analysis, Netherlands epidemiology, Odds Ratio, Postoperative Complications physiopathology, Severity of Illness Index, Treatment Outcome, Blood Pressure, Endovascular Procedures, Hypertension epidemiology, Intracranial Hemorrhages epidemiology, Ischemic Stroke surgery, Mortality, Postoperative Complications epidemiology
- Abstract
Background and Purpose: Optimal blood pressure (BP) targets before endovascular treatment (EVT) for acute ischemic stroke are unknown. We aimed to assess the relation between admission BP and clinical outcomes and successful reperfusion after EVT., Methods: We used data from the MR CLEAN (Multicenter Randomized Controlled Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry, an observational, prospective, nationwide cohort study of patients with ischemic stroke treated with EVT in routine clinical practice in the Netherlands. Baseline systolic BP (SBP) and diastolic BP (DBP) were recorded on admission. The primary outcome was the score on the modified Rankin Scale at 90 days. Secondary outcomes included successful reperfusion (extended Thrombolysis in Cerebral Infarction score 2B-3), symptomatic intracranial hemorrhage, and 90-day mortality. Multivariable logistic and linear regression were used to assess the associations of SBP and DBP with outcomes. The relations between BPs and outcomes were tested for nonlinearity. Parameter estimates were calculated per 10 mm Hg increase or decrease in BP., Results: We included 3180 patients treated with EVT between March 2014 and November 2017. The relations between admission SBP and DBP with 90-day modified Rankin Scale scores and mortality were J-shaped, with inflection points around 150 and 81 mm Hg, respectively. An increase in SBP above 150 mm Hg was associated with poor functional outcome (adjusted common odds ratio, 1.09 [95% CI, 1.04-1.15]) and mortality at 90 days (adjusted odds ratio, 1.09 [95% CI, 1.03-1.16]). Following linear relationships, higher SBP was associated with a lower probability of successful reperfusion (adjusted odds ratio, 0.97 [95% CI, 0.94-0.99]) and with the occurrence of symptomatic intracranial hemorrhage (adjusted odds ratio, 1.06 [95% CI, 0.99-1.13]). Results for DBP were largely similar., Conclusions: In patients with acute ischemic stroke treated with EVT, higher admission BP is associated with lower probability of successful reperfusion and with poor clinical outcomes. Further research is needed to investigate whether these patients benefit from BP reduction before EVT.
- Published
- 2020
- Full Text
- View/download PDF
39. Clinical and Imaging Determinants of Collateral Status in Patients With Acute Ischemic Stroke in MR CLEAN Trial and Registry.
- Author
-
Wiegers EJA, Mulder MJHL, Jansen IGH, Venema E, Compagne KCJ, Berkhemer OA, Emmer BJ, Marquering HA, van Es ACGM, Sprengers ME, van Zwam WH, van Oostenbrugge RJ, Roos YBWEM, Majoie CBLM, Roozenbeek B, Lingsma HF, Dippel DWJ, and van der Lugt A
- Subjects
- Age Factors, Aged, Aged, 80 and over, Blood Pressure, Carotid Artery Diseases epidemiology, Cerebral Angiography, Computed Tomography Angiography, Diastole, Female, Humans, Infarction, Middle Cerebral Artery epidemiology, Male, Middle Aged, Multivariate Analysis, Netherlands epidemiology, Peripheral Arterial Disease epidemiology, Randomized Controlled Trials as Topic, Registries, Sex Factors, Stroke, Blood Glucose metabolism, Carotid Artery Diseases diagnostic imaging, Carotid Artery, Internal diagnostic imaging, Collateral Circulation, Infarction, Middle Cerebral Artery diagnostic imaging
- Abstract
Background and Purpose- Collateral circulation status at baseline is associated with functional outcome after ischemic stroke and effect of endovascular treatment. We aimed to identify clinical and imaging determinants that are associated with collateral grade on baseline computed tomography angiography in patients with acute ischemic stroke due to an anterior circulation large vessel occlusion. Methods- Patients included in the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands; n=500) and MR CLEAN Registry (n=1488) were studied. Collateral status on baseline computed tomography angiography was scored from 0 (absent) to 3 (good). Multivariable ordinal logistic regression analyses were used to test the association of selected determinants with collateral status. Results- In total, 1988 patients were analyzed. Distribution of the collateral status was as follows: absent (7%, n=123), poor (32%, n=596), moderate (39%, n=735), and good (23%, n=422). Associations for a poor collateral status in a multivariable model existed for age (adjusted common odds ratio, 0.92 per 10 years [95% CI, 0.886-0.98]), male (adjusted common odds ratio, 0.64 [95% CI, 0.53-0.76]), blood glucose level (adjusted common odds ratio, 0.97 [95% CI, 0.95-1.00]), and occlusion of the intracranial segment of the internal carotid artery with occlusion of the terminus (adjusted common odds ratio 0.50 [95% CI, 0.41-0.61]). In contrast to previous studies, we did not find an association between cardiovascular risk factors and collateral status. Conclusions- Older age, male sex, high glucose levels, and intracranial internal carotid artery with occlusion of the terminus occlusions are associated with poor computed tomography angiography collateral grades in patients with acute ischemic stroke eligible for endovascular treatment.
- Published
- 2020
- Full Text
- View/download PDF
40. Letter by Mulder et al Regarding Article, "2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: a Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association".
- Author
-
Mulder MJHL, Lingsma HF, and Dippel DWJ
- Subjects
- American Heart Association, Humans, Ischemia, United States, Brain Ischemia, Ischemic Attack, Transient, Stroke
- Published
- 2019
- Full Text
- View/download PDF
41. Effect of Interhospital Transfer on Endovascular Treatment for Acute Ischemic Stroke.
- Author
-
Venema E, Groot AE, Lingsma HF, Hinsenveld W, Treurniet KM, Chalos V, Zinkstok SM, Mulder MJHL, de Ridder IR, Marquering HA, Schonewille WJ, Wermer MJH, Majoie CBLM, Roos YBWEM, Dippel DWJ, Coutinho JM, and Roozenbeek B
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Netherlands, Prospective Studies, Registries, Time-to-Treatment, Treatment Outcome, Brain Ischemia therapy, Endovascular Procedures, Patient Transfer, Stroke therapy
- Abstract
Background and Purpose- To assess the effect of inter-hospital transfer on time to treatment and functional outcome after endovascular treatment (EVT) for acute ischemic stroke, we compared patients transferred from a primary stroke center to patients directly admitted to an intervention center in a large nationwide registry. Methods- MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry is an ongoing, prospective, observational study in all centers that perform EVT in the Netherlands. We included adult patients with an acute anterior circulation stroke who received EVT between March 2014 to June 2016. Primary outcome was time from arrival at the first hospital to arterial groin puncture. Secondary outcomes included the 90-day modified Rankin Scale score and functional independence (modified Rankin Scale score of 0-2). Results- In total 821/1526 patients, (54%) were transferred from a primary stroke center. Transferred patients less often had prestroke disability (227/800 [28%] versus 255/699 [36%]; P=0.02) and more often received intravenous thrombolytics (659/819 [81%] versus 511/704 [73%]; P<0.01). Time from first presentation to groin puncture was longer for transferred patients (164 versus 104 minutes; P<0.01, adjusted delay 57 minutes [95% CI, 51-62]). Transferred patients had worse functional outcome (adjusted common OR, 0.75 [95% CI, 0.62-0.90]) and less often achieved functional independence (244/720 [34%] versus 289/681 [42%], absolute risk difference -8.5% [95% CI, -8.7 to -8.3]). Conclusions- Interhospital transfer of patients with acute ischemic stroke is associated with delay of EVT and worse outcomes in routine clinical practice, even in a country where between-center distances are short. Direct transportation of patients potentially eligible for EVT to an intervention center may improve functional outcome.
- Published
- 2019
- Full Text
- View/download PDF
42. Safety and Outcome of Endovascular Treatment for Minor Ischemic Stroke: Results From the Multicenter Clinical Registry of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands.
- Author
-
Goldhoorn RB, Mulder MJHL, Jansen IGH, van Zwam WH, Staals J, van der Lugt A, Dippel DWJ, Lingsma HF, Vos JA, Boiten J, van den Wijngaard IR, Majoie CBLM, Roos YBWEM, and van Oostenbrugge RJ
- Subjects
- Aged, Brain Ischemia diagnosis, Brain Ischemia mortality, Brain Ischemia physiopathology, Cerebrovascular Circulation, Clinical Decision-Making, Disability Evaluation, Female, Humans, Intracranial Hemorrhages etiology, Male, Middle Aged, Netherlands, Patient Selection, Prospective Studies, Recovery of Function, Registries, Risk Factors, Severity of Illness Index, Stroke diagnosis, Stroke mortality, Time Factors, Treatment Outcome, Brain Ischemia therapy, Endovascular Procedures adverse effects, Endovascular Procedures mortality, Stroke therapy
- Abstract
Goal: Insufficient data is available about safety and efficacy of endovascular treatment (EVT) in patients with minor stroke symptoms because these patients were excluded from most randomized trials. We aimed to compare characteristics, functional outcome, and complications in patients with minor ischemic stroke National Institutes of Health Stroke Scale score ≤5 (NIHSS score ≤5) and moderate to severe ischemic stroke (NIHSS score ≥6) due to intracranial proximal artery occlusion of the anterior circulation who underwent EVT., Materials and Methods: We report patients with an anterior circulation occlusion who were included between March 2014 and June 2016 in the multicenter randomized clinical trial of EVT of acute ischemic stroke in the Netherlands Registry, a prospective, multicenter, observational study for stroke centers that perform EVT in the Netherlands. Minor ischemic stroke was defined as baseline NIHSS score of 5 or less. Primary outcome is the modified Rankin Scale (mRS) score at 90 days. Secondary outcomes include symptomatic intracranial hemorrhage (sICH) and mortality., Findings: Seventy-one (5.5%) patients had a NIHSS score of 5 or less. Functional independence (mRS 0-2 at 90 days) was reached in 75% of these patients, compared to 40% of patients with NIHSS score of 6 or more. sICH occurred in 4% of patients, of which 1% occurred peri-interventionally. Death occurred in 6% of patients., Conclusions: Patients with minor ischemic stroke with an intracranial proximal arterial occlusion of the anterior circulation who underwent EVT have a high chance of favorable outcome and appear to have low occurrence of treatment-related sICH. Therefore, our results encourage the use of EVT for minor ischemic stroke in the absence of effect estimates from controlled studies., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
43. Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke.
- Author
-
Compagne KCJ, van der Sluijs PM, van den Wijngaard IR, Roozenbeek B, Mulder MJHL, van Zwam WH, Emmer BJ, Majoie CBLM, Yoo AJ, Lycklama À Nijeholt GJ, Lingsma HF, Dippel DWJ, van der Lugt A, and van Es ACGM
- Subjects
- Aged, Disease-Free Survival, Female, Humans, Male, Middle Aged, Netherlands epidemiology, Survival Rate, Endovascular Procedures, Infarction, Middle Cerebral Artery mortality, Infarction, Middle Cerebral Artery surgery, Middle Cerebral Artery surgery, Registries, Stroke mortality, Stroke surgery
- Abstract
Background and Purpose- It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant caliber M2 division occlusions were studied. Methods- Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended Thrombolysis in Cerebral Infarction ≥2B), and safety outcomes were also investigated. Associations between occlusion location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors. Results- In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted common odds ratio, 1.24; 95% CI, 0.87-1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, -2±10 for dominant M2, -5±5 for nondominant M2, and -4±9 [ P=0.24] for M1 occlusions). Furthermore, the effect of reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% CI, 1.06-1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93-1.87 for nondominant M2; and common odds ratio, 1.35; 95% CI, 1.24-1.46 for M1 occlusions). Conclusions- Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be routinely excluded from EVT.
- Published
- 2019
- Full Text
- View/download PDF
44. Personalized Prehospital Triage in Acute Ischemic Stroke.
- Author
-
Venema E, Lingsma HF, Chalos V, Mulder MJHL, Lahr MMH, van der Lugt A, van Es ACGM, Steyerberg EW, Hunink MGM, Dippel DWJ, and Roozenbeek B
- Subjects
- Acute Disease, Aged, Brain Ischemia etiology, Decision Trees, Endovascular Procedures, Hospitals, Special, Humans, Intracranial Thrombosis complications, Intracranial Thrombosis diagnosis, Intracranial Thrombosis drug therapy, Intracranial Thrombosis surgery, Male, Patient Transfer, Rural Population, Severity of Illness Index, Thrombolytic Therapy, Time-to-Treatment, Tissue Plasminogen Activator therapeutic use, Transportation of Patients, Treatment Outcome, Urban Population, Brain Ischemia diagnosis, Emergency Medical Services, Precision Medicine, Triage
- Abstract
Background and Purpose- Direct transportation to a center with facilities for endovascular treatment might be beneficial for patients with acute ischemic stroke, but it can also cause harm by delay of intravenous treatment. Our aim was to determine the optimal prehospital transportation strategy for individual patients and to assess which factors influence this decision. Methods- We constructed a decision tree model to compare outcome of ischemic stroke patients after transportation to a primary stroke center versus a more distant intervention center. The optimal strategy was estimated based on individual patient characteristics, geographic location, and workflow times. In the base case scenario, the primary stroke center was located at 20 minutes and the intervention center at 45 minutes. Additional sensitivity analyses included an urban scenario (10 versus 20 minutes) and a rural scenario (30 versus 90 minutes). Results- Direct transportation to the intervention center led to better outcomes in the base case scenario when the likelihood of a large vessel occlusion as a cause of the ischemic stroke was >33%. With a high likelihood of large vessel occlusion (66%, comparable with a Rapid Arterial Occlusion Evaluation score of 5 or above), the benefit of direct transportation to the intervention center was 0.10 quality-adjusted life years (=36 days in full health). In the urban scenario, direct transportation to an intervention center was beneficial when the risk of large vessel occlusion was 24% or higher. In the rural scenario, this threshold was 49%. Other factors influencing the decision included door-to-needle times, door-to-groin times, and the door-in-door-out time. Conclusions- The preferred prehospital transportation strategy for suspected stroke patients depends mainly on the likelihood of large vessel occlusion, driving times, and in-hospital workflow times. We constructed a robust model that combines these characteristics and can be used to personalize prehospital triage, especially in more remote areas.
- Published
- 2019
- Full Text
- View/download PDF
45. Time to Endovascular Treatment and Outcome in Acute Ischemic Stroke: MR CLEAN Registry Results.
- Author
-
Mulder MJHL, Jansen IGH, Goldhoorn RB, Venema E, Chalos V, Compagne KCJ, Roozenbeek B, Lingsma HF, Schonewille WJ, van den Wijngaard IR, Boiten J, Albert Vos J, Roos YBWE, van Oostenbrugge RJ, van Zwam WH, Majoie CBLM, van der Lugt A, and Dippel DWJ
- Subjects
- Acute Disease, Humans, Myocardial Ischemia epidemiology, Myocardial Ischemia mortality, Netherlands epidemiology, Patient Selection, Stroke epidemiology, Stroke mortality, Treatment Outcome, Endovascular Procedures, Myocardial Ischemia therapy, Stroke therapy, Time Factors
- Abstract
Background: Randomized, clinical trials in selected acute ischemic stroke patients reported that for every hour delay of endovascular treatment (EVT), chances of functional independence diminish by up to 3.4%. These findings may not be fully generalizable to clinical practice because of strict in- and exclusion criteria in these trials. Therefore, we aim to assess the association of time to EVT with functional outcome in current, everyday clinical practice., Methods: The MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in The Netherlands) is an ongoing, prospective, observational study in all centers that perform EVT in The Netherlands. Data were analyzed from patients treated between March 2014 and June 2016. In the primary analysis we assessed the association of time from stroke onset to start of EVT and time from stroke onset to successful reperfusion with functional outcome (measured with the modified Rankin Scale), by means of ordinal logistic regression., Results: We analyzed 1488 patients with acute ischemic stroke who underwent EVT. An increased time to start of EVT was associated with worse functional outcome (adjusted common odds ratio, 0.83 per hour; 95% confidence interval, 0.77-0.89) and a 2.2% increase in mortality. Every hour increase from stroke onset to EVT start resulted in a 5.3% decreased probability of functional independence (modified Rankin Scale, 0-2). In the 742 patients with successful reperfusion, every hour increase from stroke onset to reperfusion was associated with a 7.7% decreased probability of functional independence., Conclusions: Time to EVT for acute ischemic stroke in current clinical practice is strongly associated with functional outcome. Our data suggest that this association might be even stronger than previously suggested in reports on more selected patient populations from randomized, controlled trials. These findings emphasize that functional outcome of EVT patients can be greatly improved by shortening onset to treatment times., (© 2018 American Heart Association, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
46. Persistent orofacial muscle pain: Its synonymous terminology and presentation.
- Author
-
Spierings ELH and Mulder MJHL
- Subjects
- Adult, Age of Onset, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Facial Pain diagnosis, Temporomandibular Joint Disorders diagnosis, Terminology as Topic
- Abstract
Objective: The purpose of the present paper is to describe the presentation of persistent orofacial muscle pain, also commonly referred to as myofascial temporomandibular disorder., Methods: In this practice survey, the authors reviewed the demographic and clinical features of 34 patients who were evaluated and diagnosed personally., Results: The majority of the 34 patients were women (82.4%), and their age at consultation averaged 44.6 ± 12.6 (SD) years. The median pain duration was 4.0 years (range: 0.2-34 years). In 97.1% of patients, the pain occurred daily and continuously, and in 51.9% it was unilateral. Chewing or eating made the pain worse in 50% of the patients, and talking in 29.4%. On examination, tightness of the masseter muscle(s) was present in 58.8%, and tenderness in 58.8%., Conclusions: Persistent orofacial muscle pain mostly affects women, generally occurs daily and continuously, and is equally often unilateral and bilateral. Chewing, eating, and talking are the most common aggravating factors, and tightness or tenderness of the masseter muscle(s) is often found on examination.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.